The CJC-1295 ipamorelin blend research peptide represents a significant area of investigation for researchers exploring growth hormone (GH) regulation and related physiological processes. This combination pairs two peptides that reach the same endpoint — GH secretion — through separate receptor systems, which is precisely why it is of interest as a research tool. Scientists use this blend to investigate the hypothalamic-pituitary-somatotropic axis and the way distinct signalling inputs converge on the somatotroph cell. Understanding the intricacies of GH release and its downstream effects remains relevant to fields ranging from endocrine physiology to metabolic research. Dynamite Research Peptides supplies the CJC-1295 ipamorelin blend research peptide for research use only, with third-party analytical documentation supplied for every lot.
Research Background
The development of both components stems from efforts to improve upon native signalling peptides that are impractical for sustained laboratory work. Endogenous growth hormone-releasing hormone (GHRH) is cleared rapidly in circulation, which limits its usefulness as a research input. CJC-1295 is an analog of the biologically active GHRH(1-29) fragment, modified to resist enzymatic degradation and to extend its duration of activity relative to native GHRH. Two forms circulate in the research literature and in supplier catalogues: a version bearing a drug-affinity complex that binds serum albumin to prolong exposure, and a "no-DAC" modified GRF(1-29) form without that modification. Ipamorelin arose from a separate line of work on growth hormone-releasing peptides. It is a synthetic pentapeptide developed in the 1990s at Novo Nordisk and was characterised as the first highly selective growth hormone secretagogue. Combining the two, as in the CJC-1295 ipamorelin blend research peptide, gives researchers a way to probe GHRH-receptor and ghrelin-receptor signalling within a single preparation.
Mechanism of Action
CJC-1295 acts at the GHRH receptor (GHRH-R), a G-protein-coupled receptor expressed on anterior pituitary somatotrophs. Receptor engagement raises intracellular cyclic AMP and activates protein kinase A, promoting both the synthesis and the release of stored growth hormone. Its structural modifications slow enzymatic breakdown, so the signal it delivers is longer-lived than that of native GHRH; in the albumin-binding form, that exposure is extended further still.
Ipamorelin operates through a different receptor entirely. It binds the growth hormone secretagogue receptor (GHS-R1a), the same receptor targeted by ghrelin, and signals predominantly through the phospholipase C pathway with a resulting rise in intracellular calcium. Its defining characteristic in the published literature is selectivity: unlike earlier growth hormone-releasing peptides, ipamorelin produced GH release without meaningful accompanying release of ACTH, cortisol or prolactin in the studies that first characterised it.
Because the two peptides engage separate receptors that converge on the same secretory cell, their combined effect on GH output has been reported as greater than either input alone. That convergence is the mechanistic reason the blend is studied as a single preparation.
Published Research Overview
Several peer-reviewed publications underpin research interest in the CJC-1295 ipamorelin blend research peptide, though it is worth noting that the published record largely characterises the two components separately rather than as a fixed combination.
Ipamorelin was introduced to the literature by Raun and colleagues in the European Journal of Endocrinology in 1998, in a paper describing it as the first selective growth hormone secretagogue. That work established both its GH-releasing activity and the selectivity profile — minimal ACTH and cortisol response — that distinguished it from the growth hormone-releasing peptides that preceded it.
On the CJC-1295 side, Jetté and colleagues reported in Endocrinology in 2005 on hGRF(1-29)-albumin bioconjugates and their activation of the GRF receptor on the rat anterior pituitary, providing the receptor-level basis for the albumin-binding design. Teichman and colleagues followed in the Journal of Clinical Endocrinology & Metabolism in 2006 with a study of prolonged GH and IGF-1 secretion in healthy adults following administration of the long-acting GHRH analog. A companion report by Ionescu and Frohman in the same journal and year examined whether the pulsatile character of GH secretion is preserved under continuous stimulation by the analog — a question central to interpreting any sustained-exposure GHRH input.
Taken together, these publications describe receptor pharmacology, secretory kinetics and selectivity, and they form the starting point most investigators use when designing work with the blend. Researchers should consult the primary sources directly rather than relying on secondary summaries.
Storage & Handling
The CJC-1295 ipamorelin blend research peptide from Dynamite Research Peptides is supplied lyophilized to maximise stability. Store the sealed vial protected from light and moisture; long-term storage at -20°C is standard for lyophilized material, and short-term refrigeration is generally acceptable for unopened vials. Reconstitute only with an appropriate sterile solvent immediately before laboratory use, and avoid repeated freeze-thaw cycles, which accelerate degradation. Proper handling preserves both the integrity of the compound and the reproducibility of results.
Conclusion
The CJC-1295 ipamorelin blend research peptide gives investigators a way to study two convergent GH-secretagogue pathways in a single preparation. Its research value depends entirely on knowing what is in the vial: identity, purity and lot traceability. Dynamite Research Peptides supplies material at 99%+ purity with a Certificate of Analysis for every lot, so that analytical characterisation is documented rather than assumed.
Frequently Asked Questions
Q: What does the Certificate of Analysis tell me?
A: The COA supplied with our CJC-1295 ipamorelin blend research peptide reports third-party analytical results confirming identity and purity for that specific lot, and it is tied to the lot number printed on the vial. It is the document that lets a researcher verify what was actually received rather than relying on a catalogue description.
Q: How is purity determined?
A: Purity is assessed by high-performance liquid chromatography, with identity confirmed by mass spectrometry. Our specification is 99%+ purity, and the supporting data appear on the lot's COA.
Q: What is the difference between the DAC and no-DAC forms of CJC-1295?
A: The DAC form carries a drug-affinity complex that binds serum albumin, substantially extending how long the peptide remains in circulation. The no-DAC form, often listed as modified GRF(1-29), lacks that modification and clears far more quickly. Which form a blend contains materially affects experimental design, so check the COA and product specification before use.
All products are for research use only — not for human or animal consumption.